[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495349":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":41,"locations":46,"responsibleParty":104,"collaborators":106,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":27,"enrollmentInfo":125,"targetDuration":27,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":48,"whyStopped":27,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"IRCCS Centro San Giovanni di Dio Fatebenefratelli","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Active tDCS plus individualized language training","EXPERIMENTAL","The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training",[13,14],"Device: Active tDCS","Behavioral: individualized language training",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo tDCS plus individualized language training","ACTIVE_COMPARATOR","The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training",[14,20],"Device: Placebo tDCS",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","Active tDCS","Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);",[9],null,{"type":29,"name":30,"description":30,"armGroupLabels":31,"otherNames":27},"BEHAVIORAL","individualized language training",[9,16],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Placebo tDCS","Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);",[16],[37],{"name":38,"affiliation":39,"role":40},"Maria Cotelli","IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli","PRINCIPAL_INVESTIGATOR",[42],{"name":38,"role":43,"phone":44,"phoneExt":27,"email":45},"CONTACT","00390303501457","mcotelli@fatebenefratelli.eu",[47,63,78,89],{"facility":38,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Brescia","BS","25125","Italy","IT",{"type":55,"coordinates":56},"Point",[57,58],10.21472,45.53558,{"lat":58,"lon":57},[61],{"name":62,"role":43,"phone":44,"phoneExt":27,"email":45},"Maria Cotelli, PhD",{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Tiziana Carandini","Milan","MI","20122",{"type":55,"coordinates":69},[70,71],9.18951,45.46427,{"lat":71,"lon":70},[74],{"name":75,"role":43,"phone":76,"phoneExt":27,"email":77},"Tiziana Carandini, MD","00390255033814","tiziana.carandini@policlinico.mi.it",{"facility":79,"status":48,"city":65,"state":66,"zip":80,"country":52,"countryCode":53,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Francesca Baglio","20148",{"type":55,"coordinates":82},[70,71],{"lat":71,"lon":70},[85],{"name":86,"role":43,"phone":87,"phoneExt":27,"email":88},"Francesca Baglio, MD","00390240308069","fbaglio@dongnocchi.it",{"facility":90,"status":48,"city":91,"state":92,"zip":93,"country":52,"countryCode":53,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Stefano F. Cappa","Pavia","PV","27100",{"type":55,"coordinates":95},[96,97],9.15917,45.19205,{"lat":97,"lon":96},[100],{"name":101,"role":43,"phone":102,"phoneExt":27,"email":103},"Stefano Cappa, MD","00390382380351","stefano.cappa@mondino.it",{"type":105,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[107,109,111,113],{"name":108,"class":6},"Fondazione Regionale per la Ricerca Biomedica",{"name":110,"class":6},"IRCCS National Neurological Institute \"C. Mondino\" Foundation",{"name":112,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"name":114,"class":115},"IRCCS Fondazione Don Carlo Gnocchi - ONLUS, Milan","UNKNOWN","100495349","a-multimodal-approach-for-clinical-diagnosis-and-treatment-of-primary-progressive-aphasia-mainstream-id3430931-100495349",false,"NCT05730023","A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931","MAINSTREAM","Inclusion Criteria:\n\n* Diagnosis PPA according to the current clinical criteria (Gorno-Tempini et al., 2011);\n* Mild PPA defined using the Progressive Aphasia Severity Scale (PASS);\n* Italian native speakers.\n\nExclusion Criteria:\n\n* Presence of developmental disorders;\n* Presence of any medical or psychiatric illness that could interfere in completing assessments;\n* Presence of any medical condition that represents a contraindication to tDCS.","ALL","40 Years",{"count":126,"type":127},60,"ESTIMATED","INTERVENTIONAL",[130],"NA","Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment).\n\nThis objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).",[133],"Primary Progressive Aphasia",[135,136],"Behavioral and neural effects of tDCS combined with language training","Alzheimer's disease and other dementias","2024-09-06",{"date":139,"type":140},"2024-09-19","ACTUAL",{"date":142,"type":140},"2023-02-01",{"date":144,"type":127},"2026-02",{"name":5,"class":6},4]